Rx License-Rx

TAB-2041

RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses

The retinoid-related orphan receptor gamma (RORgamma) is a member of the nuclear receptor superfamily. NIH investigators used homologous recombination in embryonic stem cells to generate mice in which the RORgamma gene was disrupted. RORgamma deficient mice lack peripheral and mesenteric lymph nodes and Peyer's patches indicating that ROR expression is indispensable for lymph node organogenesis. In addition, RORgamma is required for the generation of Th17 cells which play a critical role in autoimmune disease. The RORgamma deficient mice are useful to identify the physiological functions of the RORgamma. RORgamma deficient mice also provide an excellent tool to study the role of RORgamma in immune responses and autoimmune disease, the study of the role of Th17 and interleukin 17 in these processes, and the analysis. Source institute: NIEHS. Inventors: Jetten, Anton.

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Immunology

Indication: Autoimmune disease

Modality: Cell/Gene Therapy

Focus tags: Immunology, Ophthalmology, Rare Disease

Technology tags: Cell/Gene Therapy, Diagnostic / Biomarker

Mechanism:

Development stage: Preclinical

Patent status: Research Material

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Immunology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Autoimmune disease. Public description: The retinoid-related orphan receptor gamma (RORgamma) is a member of the nuclear receptor superfamily. NIH investigators used homologous recombination in embryonic stem cells to generate mice in which the RORgamma gene was disrupted.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

The eye can create faster proof: Local delivery, imaging endpoints, and smaller patient groups can make ophthalmology assets easier to de-risk than broad systemic programs.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Regeneron — Retina commercial leadership and appetite for durability/delivery improvements. Roche — Ophthalmology franchise plus biologics and delivery infrastructure. Astellas / Iveric — Retina specialization and complement/orphan-eye adjacency.

Development Strategy to Increase PoS

First indication: Autoimmune disease

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Reframe as a localized orphan-retina or front-of-eye precision program Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Reframe as a localized orphan-retina or front-of-eye precision program

Best next experiment: Run the smallest independent study that validates: Switch from systemic exposure to intravitreal, topical, or depot delivery and use OCT/ERG/imaging biomarkers as early go/no-go endpoints.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.